We are convinced that early detection of diseases is the prerequisite for better treatment options and thus optimal chances of recovery.
That is why we are driven by the vision of making chronic health imbalances diagnosable even before the disease can manifest itself. This is the prerequisite for turning the early detection of life-changing diseases such as cancer, Alzheimer’s or diabetes into true prevention.
Our aim is to make our diagnostics as simple, cost-effective, and burden-free as possible so that as many people as possible can benefit from them.
When our organism slips and runs in the direction of disease, our immune system is often the first to recognize this. Many times, before our body reports this in form of symptoms. As experts in medical technologies, our profound understanding of immunological processes helps us to use these processes for the detection of pathological activity. The platform technology we have developed, EDIM® (Epitope Detection in Monocytes), uses mechanisms of the immune system to detect such aberrations. The EDIM Technology screens macrophages for antigens that have previously been taken up into the cell interior by these immune cells through phagocytosis – this is why we also refer to EDIM® as a immunological biopsy.
With the PanTum Detect® blood test, we have developed a screening test that detects tumor-independent, cancerous immunological processes at a very early stage. This has been proven in a large-scale prospective study (study publication) at the University Medical Center Hamburg-Eppendorf.
In this study, 5,000 healthy study participants were examined with PanTum Detect®. Participants with suspicious results were subsequently diagnosed with imaging techniques such as PET/CT and MRI. In 82% of this group, a previously asymptomatic, undetected malignant tumor or a premalignant lesion was detected. And this from 29 different tumor types.
The development of tumors into a life-threatening disease usually happens over many years. For many patients, symptoms do not appear until the tumor grows invasively and spreads. The key is therefore to detect the tumors before the first symptoms appear. This is exactly where we come in.
Zyagnum AG is a biotechnology company with the mission to detect serious diseases at the earliest possible stage and thus enable optimal treatment options. We have been working since 2007 to develop technologies that will enable us to achieve this goal. With the development of our EDIM® platform technology, we have taken a major step in the right direction.